{"type":"trials","record":{"id":42058,"source_id":"clinicaltrials-gov","external_id":"NCT06165068","title":"Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study","brief_summary":"The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen. Participants will divided in to three groups. * Participants who were already taking low dose antiplatelet medications. * Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator * Participants does not use any medications.","overall_status":"Recruiting","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Navamindradhiraj University","enrollment":174,"countries":["Thailand"],"start_date":"2023-12-01","completion_date":"2026-09-01","last_update_date":"2023-12-15","source_url":"https://clinicaltrials.gov/study/NCT06165068","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 85 Years","comparator":"Antiplatelet drug; No medication","organization":"Navamindradhiraj University","interventions":["Aspirin 81Mg Ec Tab","Clopidogrel","N-acetylcysteine"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Drusen volume analysis — 1 year","Best-corrected visual acuity change — 1 year","Rate of disease progression — 1 year","Side effects of medications intake — 1 year"],"design_description":"NON RANDOMIZED · PARALLEL · PREVENTION · NONE","source_has_results":false},"controlled_terms":["Dry Age-related Macular Degeneration","Aspirin 81Mg Ec Tab","Clopidogrel","N-acetylcysteine"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06165068","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-12-01 to 2026-09-01","comparator":"Antiplatelet drug; No medication","confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.913Z","intervention":["Aspirin 81Mg Ec Tab","Clopidogrel","N-acetylcysteine"],"participants":174,"study_design":"NON RANDOMIZED · PARALLEL · PREVENTION · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Drusen volume analysis — 1 year","Best-corrected visual acuity change — 1 year","Rate of disease progression — 1 year","Side effects of medications intake — 1 year"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42058","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}